

# Olli Kallioniemi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3942583/olli-kallioniemi-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

376  
papers

44,694  
citations

99  
h-index

206  
g-index

460  
ext. papers

48,888  
ext. citations

8.5  
avg, IF

6.54  
L-index

#	Paper	IF	Citations
376	Tissue microarrays for high-throughput molecular profiling of tumor specimens. <i>Nature Medicine</i> , <b>1998</b> , 4, 844-7	50.5	3329
375	Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. <i>Science</i> , <b>1992</b> , 258, 818-21	33.3	2764
374	Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. <i>American Journal of Human Genetics</i> , <b>2003</b> , 72, 1117-30	11	2643
373	International network of cancer genome projects. <i>Nature</i> , <b>2010</b> , 464, 993-8	50.4	1613
372	Gene-expression profiles in hereditary breast cancer. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 539-48	39.2	1462
371	High frequency of BRAF mutations in nevi. <i>Nature Genetics</i> , <b>2003</b> , 33, 19-20	36.3	1355
370	AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. <i>Science</i> , <b>1997</b> , 277, 965-8	33.3	1340
369	In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <i>Nature Genetics</i> , <b>1995</b> , 9, 401-6	36.3	1166
368	Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. <i>Genes Chromosomes and Cancer</i> , <b>1994</b> , 10, 231-43	5	1065
367	Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. <i>Science</i> , <b>1996</b> , 274, 1371-4	33.3	635
366	Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1994</b> , 91, 2156-60	11.5	602
365	Evidence for a prostate cancer susceptibility locus on the X chromosome. <i>Nature Genetics</i> , <b>1998</b> , 20, 175-8	36.3	592
364	Somatic STAT3 mutations in large granular lymphocytic leukemia. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1905-13	59.2	535
363	Tissue microarrays for rapid linking of molecular changes to clinical endpoints. <i>American Journal of Pathology</i> , <b>2001</b> , 159, 2249-56	5.8	471
362	Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1991-6	5.8	453
361	A community effort to assess and improve drug sensitivity prediction algorithms. <i>Nature Biotechnology</i> , <b>2014</b> , 32, 1202-12	44.5	447
360	ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 5321-5	11.5	442

359	Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. <i>Nature Genetics</i> , <b>2002</b> , 30, 181-4	36.3	418
358	Tissue microarray technology for high-throughput molecular profiling of cancer. <i>Human Molecular Genetics</i> , <b>2001</b> , 10, 657-62	5.6	418
357	Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. <i>Oncogene</i> , <b>2003</b> , 22, 2021-33	9.2	380
356	Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. <i>Cancer Research</i> , <b>2011</b> , 71, 3236-45	10.1	363
355	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. <i>British Journal of Cancer</i> , <b>2008</b> , 98, 1457-66	8.7	358
354	MicroRNA in prostate, bladder, and kidney cancer: a systematic review. <i>European Urology</i> , <b>2011</b> , 59, 671-80	10.2	355
353	A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. <i>American Journal of Human Genetics</i> , <b>2002</b> , 71, 432-8	11	354
352	High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. <i>American Journal of Pathology</i> , <b>1999</b> , 154, 981-6	5.8	337
351	Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. <i>International Journal of Cancer</i> , <b>1991</b> , 49, 650-5	7.5	325
350	Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. <i>Journal of the National Cancer Institute</i> , <b>1992</b> , 84, 1109-14	9.7	319
349	Break-induced replication repair of damaged forks induces genomic duplications in human cells. <i>Science</i> , <b>2014</b> , 343, 88-91	33.3	308
348	Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1758-64	9.7	298
347	Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. <i>Journal of the National Cancer Institute</i> , <b>1992</b> , 84, 883-7	9.7	274
346	Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. <i>EMBO Journal</i> , <b>2011</b> , 30, 3962-76	13	259
345	miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. <i>PLoS ONE</i> , <b>2011</b> , 6, e16915	3.7	258
344	Genome screening by comparative genomic hybridization. <i>Trends in Genetics</i> , <b>1997</b> , 13, 405-9	8.5	249
343	Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1998</b> , 95, 8703-8	11.5	248
342	Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. <i>Cancer Discovery</i> , <b>2013</b> , 3, 1416-29	24.4	247

341	A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. <i>PLoS ONE</i> , <b>2010</b> , 5, e10431	3.7	247
340	Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 1252-9	9.7	231
339	Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 142-50	19.4	230
338	The impact of low-frequency and rare variants on lipid levels. <i>Nature Genetics</i> , <b>2015</b> , 47, 589-97	36.3	229
337	Identification of fusion genes in breast cancer by paired-end RNA-sequencing. <i>Genome Biology</i> , <b>2011</b> , 12, R6	18.3	227
336	Computer image analysis of comparative genomic hybridization. <i>Cytometry</i> , <b>1995</b> , 19, 10-26		223
335	Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. <i>Cancer</i> , <b>1988</b> , 62, 2183-90	6.4	223
334	High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. <i>American Journal of Pathology</i> , <b>2000</b> , 157, 787-94	5.8	216
333	Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. <i>Genome Biology</i> , <b>2008</b> , 9, R139	18.3	215
332	ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. <i>Nature Methods</i> , <b>2007</b> , 4, 13-7	21.6	207
331	Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. <i>Cytometry</i> , <b>1988</b> , 9, 164-9		207
330	Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. <i>Cancer Research</i> , <b>2011</b> , 71, 1956-67	10.1	206
329	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 121, 4541-50	20.2	204
328	FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. <i>Cancer Research</i> , <b>2010</b> , 70, 6735-45	10.1	203
327	Tissue microarrays (TMAs) for high-throughput molecular pathology research. <i>International Journal of Cancer</i> , <b>2001</b> , 94, 1-5	7.5	197
326	CIP2A is associated with human breast cancer aggressivity. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5092-100	12.9	190
325	TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. <i>Cancer Research</i> , <b>2006</b> , 66, 10242-6	10.1	188
324	Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. <i>Oncogene</i> , <b>2009</b> , 28, 3926-36	9.2	186

323	SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 937-48	6.7	183
322	Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. <i>Cancer</i> , <b>1988</b> , 61, 334-9	6.4	183
321	Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , <b>1995</b> , 12, 213-9	5	182
320	Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. <i>American Journal of Human Genetics</i> , <b>2002</b> , 70, 1299-304	11	181
319	Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. <i>Cancer Research</i> , <b>2005</b> , 65, 5588-98	10.1	173
318	Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 421-30	4.4	172
317	A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 34283-93	5.4	169
316	Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. <i>Nature</i> , <b>2015</b> , 519, 102-5	50.4	168
315	Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. <i>Nature Genetics</i> , <b>2004</b> , 36, 979-83	36.3	167
314	Are data from different gene expression microarray platforms comparable?. <i>Genomics</i> , <b>2004</b> , 83, 1164-8	4.3	162
313	Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. <i>Genes Chromosomes and Cancer</i> , <b>2010</b> , 49, 1062-9	5	161
312	SHARPIN is an endogenous inhibitor of $\beta$ -integrin activation. <i>Nature Cell Biology</i> , <b>2011</b> , 13, 1315-24	23.4	159
311	Molecular cytogenetic analysis of 11 new breast cancer cell lines. <i>British Journal of Cancer</i> , <b>1999</b> , 81, 1328-34	3.4	159
310	Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. <i>Cancer</i> , <b>1990</b> , 65, 1180-4	6.4	159
309	Inferring tree models for oncogenesis from comparative genome hybridization data. <i>Journal of Computational Biology</i> , <b>1999</b> , 6, 37-51	1.7	155
308	Integrin trafficking regulated by Rab21 is necessary for cytokinesis. <i>Developmental Cell</i> , <b>2008</b> , 15, 371-385	5.2	153
307	RNAi microarray analysis in cultured mammalian cells. <i>Genome Research</i> , <b>2003</b> , 13, 2341-7	9.7	153
306	Tumour DNA ploidy as an independent prognostic factor in breast cancer. <i>British Journal of Cancer</i> , <b>1987</b> , 56, 637-42	8.7	152

305	FusionCatcher - a tool for finding somatic fusion genes in paired-end RNA-sequencing data		152
304	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , <b>2014</b> , 4, 5193	4.9	150
303	Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. <i>Cell</i> , <b>2008</b> , 133, 537-48	56.2	150
302	High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6070-8	12.9	148
301	Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 1529-31	9.7	140
300	Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 9603-8	11.5	133
299	Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. <i>Oncogene</i> , <b>2007</b> , 26, 3846-56	9.2	130
298	Androgen regulation of micro-RNAs in prostate cancer. <i>Prostate</i> , <b>2011</b> , 71, 604-14	4.2	129
297	Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1987</b> , 23, 277-82		128
296	High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. <i>Molecular Oncology</i> , <b>2014</b> , 8, 93-104	7.9	127
295	High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e77232	3.7	121
294	Tissue microarrays: what will they bring to molecular and anatomic pathology?. <i>Advances in Anatomic Pathology</i> , <b>2001</b> , 8, 14-20	5.1	119
293	MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. <i>Neoplasia</i> , <b>2012</b> , 14, 868-79	6.4	117
292	Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes. <i>Theranostics</i> , <b>2017</b> , 7, 3824-3841	12.1	116
291	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 794-806	12.9	116
290	ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER. <i>Journal of Urology</i> , <b>2000</b> , 164, 1992-1995	2.5	115
289	Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 99-106	8.7	114
288	CHEK2 variant I157T may be associated with increased breast cancer risk. <i>International Journal of Cancer</i> , <b>2004</b> , 111, 543-7	7.5	114

287	ANX7, a candidate tumor suppressor gene for prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 4575-80	11.5	113
286	Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. <i>Oncogene</i> , <b>2001</b> , 20, 6718-23	9.2	109
285	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. <i>Journal of Medical Genetics</i> , <b>2005</b> , 42, 602-3	5.8	107
284	Consensus review of the clinical utility of DNA content cytometry in prostate cancer. <i>Cytometry</i> , <b>1993</b> , 14, 497-500		107
283	Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. <i>Human Molecular Genetics</i> , <b>1997</b> , 6, 2309-15	5.6	106
282	Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. <i>Cytometry</i> , <b>1994</b> , 16, 93-9		105
281	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. <i>Neoplasia</i> , <b>2004</b> , 6, 240-247	6.4	104
280	Role of ErbB4 in breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , <b>2008</b> , 13, 259-68	2.4	102
279	Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. <i>Journal of Clinical Oncology</i> , <b>1993</b> , 11, 36-43	2.2	101
278	An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. <i>Oncogene</i> , <b>2012</b> , 31, 2090-100	9.2	99
277	Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , <b>1997</b> , 20, 383-91	5	98
276	Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. <i>Oncogene</i> , <b>2012</b> , 31, 3444-56	9.2	96
275	Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKK. <i>Oncogene</i> , <b>2013</b> , 32, 4892-902	9.2	95
274	Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. <i>Cancer</i> , <b>1994</b> , 73, 652-8	6.4	94
273	Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. <i>Scientific Reports</i> , <b>2017</b> , 7, 15580	4.9	91
272	Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. <i>Oncogene</i> , <b>2006</b> , 25, 6997-7008	9.2	85
271	Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. <i>International Journal of Cancer</i> , <b>2005</b> , 113, 575-80	7.5	85
270	Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 525-36	5.8	80

269	Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. <i>Genes Chromosomes and Cancer</i> , <b>2002</b> , 35, 311-7	5	77
268	EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6450-8	12.9	76
267	Distance-based reconstruction of tree models for oncogenesis. <i>Journal of Computational Biology</i> , <b>2000</b> , 7, 789-803	1.7	76
266	Hardware and software requirements for quantitative analysis of comparative genomic hybridization. <i>Cytometry</i> , <b>1995</b> , 19, 4-9		76
265	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2014</b> , 28, 1738-42	10.7	75
264	Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 730-5	5.6	75
263	High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. <i>Oncotarget</i> , <b>2013</b> , 4, 48-63	3.3	74
262	Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. <i>British Journal of Cancer</i> , <b>1990</b> , 62, 142-6	8.7	72
261	Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry. <i>Cancer</i> , <b>1989</b> , 63, 1761-7	6.4	72
260	Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. <i>Journal of Pathology</i> , <b>1990</b> , 162, 295-301	8.4	71
259	Biochip technologies in cancer research. <i>Annals of Medicine</i> , <b>2001</b> , 33, 142-7	1.5	70
258	Visual mapping by fiber-FISH. <i>Genomics</i> , <b>1995</b> , 30, 31-6	4.3	70
257	Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization. <i>Journal of Chemical Information and Modeling</i> , <b>2014</b> , 54, 2347-59	6.1	67
256	Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 3175-85	6.1	67
255	Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. <i>Genes Chromosomes and Cancer</i> , <b>1997</b> , 20, 372-6	5	67
254	Different opinions on classification of DNA histograms produced from paraffin-embedded tissue. <i>Cytometry</i> , <b>1989</b> , 10, 711-7		67
253	Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. <i>Circulation</i> , <b>1996</b> , 93, 1079-82	16.7	67
252	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 730-735	5.6	67



251	Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. <i>Cytometry</i> , <b>1991</b> , 12, 413-21		66
250	The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 1510-7	7.5	64
249	Expression of Bcl-2 family member Bid in normal and malignant tissues. <i>Neoplasia</i> , <b>2002</b> , 4, 129-40	6.4	64
248	Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. <i>European Journal of Human Genetics</i> , <b>2000</b> , 8, 757-63	5.3	64
247	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. <i>Blood</i> , <b>2017</b> , 130, 789-802	2.2	63
246	A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes. <i>Human Genetics</i> , <b>2002</b> , 110, 111-21	6.3	63
245	Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. <i>Oncotarget</i> , <b>2011</b> , 2, 1176-90	3.3	63
244	Association of tamoxifen resistance and lipid reprogramming in breast cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 850	4.8	62
243	Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. <i>Oncogene</i> , <b>2004</b> , 23, 2264-74	9.2	62
242	Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4586-91	2.2	62
241	Identification of microRNAs inhibiting TGF- $\beta$ -induced IL-11 production in bone metastatic breast cancer cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e37361	3.7	60
240	Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. <i>European Urology</i> , <b>1997</b> , 31, 216-9	10.2	59
239	Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. <i>British Journal of Cancer</i> , <b>1988</b> , 58, 213-5	8.7	59
238	Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. <i>Journal of Proteome Research</i> , <b>2012</b> , 11, 850-60	5.6	58
237	Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. <i>British Journal of Cancer</i> , <b>1997</b> , 75, 190-5	8.7	58
236	Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 2774-81	7.5	57
235	Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. <i>Bioinformatics</i> , <b>2016</b> , 32, i455-i463	7.2	57
234	The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. <i>Molecular Oncology</i> , <b>2013</b> , 7, 392-401	7.9	56

233	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. <i>Leukemia</i> , <b>2018</b> , 32, 774-787	10.7	56
232	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. <i>Cancer Genetics and Cytogenetics</i> , <b>2000</b> , 123, 128-32		55
231	Identification of miR-193b targets in breast cancer cells and systems biological analysis of their functional impact. <i>Molecular and Cellular Proteomics</i> , <b>2011</b> , 10, M110.005322	7.6	54
230	Androgen receptor CAG polymorphism and prostate cancer risk. <i>Human Genetics</i> , <b>2002</b> , 111, 166-71	6.3	54
229	CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. <i>Analytical Cellular Pathology</i> , <b>2001</b> , 22, 229-34		53
228	Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple isoforms. <i>PLoS ONE</i> , <b>2012</b> , 7, e48745	3.7	53
227	Consistency in drug response profiling. <i>Nature</i> , <b>2016</b> , 540, E5-E6	50.4	53
226	Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. <i>Cancer Research</i> , <b>2006</b> , 66, 743-7	10.1	51
225	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 71, 319-327	10.2	50
224	c-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cells. <i>Molecular and Cellular Biology</i> , <b>2012</b> , 32, 3513-26	4.8	50
223	New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 812-8	9.7	50
222	Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity. <i>Oncogene</i> , <b>2001</b> , 20, 6881-90	9.2	50
221	PD-L1 tumor-associated macrophages and PD-1 tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. <i>Haematologica</i> , <b>2018</b> , 103, 1908-1914	6.6	49
220	Functional evidence implicating S100P in prostate cancer progression. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 330-339	7.5	49
219	Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. <i>Blood Cancer Journal</i> , <b>2013</b> , 3, e168	7	48
218	A cell spot microarray method for production of high density siRNA transfection microarrays. <i>BMC Genomics</i> , <b>2011</b> , 12, 162	4.5	48
217	Quality control of CGH: impact of metaphase chromosomes and the dynamic range of hybridization. <i>Cytometry</i> , <b>1997</b> , 28, 198-205		48
216	Biology and natural history of breast cancer. <i>International Journal of Cancer</i> , <b>1990</b> , 5, 5-21	7.5	48

215	Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. <i>Analytical Cellular Pathology</i> , <b>2006</b> , 28, 315-26	3.4	48
214	Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. <i>Genes Chromosomes and Cancer</i> , <b>1999</b> , 24, 56-61	5	47
213	A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. <i>Genomics</i> , <b>1995</b> , 26, 134-7	4.3	47
212	Frequent loss of the 11q14-24 region in chronic lymphocytic leukemia: a study by comparative genomic hybridization. Tampere CLL Group. <i>Genes Chromosomes and Cancer</i> , <b>1997</b> , 19, 286-90	5	46
211	CHEK2 1100delC is not a risk factor for male breast cancer population. <i>International Journal of Cancer</i> , <b>2004</b> , 108, 475-6	7.5	46
210	Genome-wide scan for linkage in finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. <i>Prostate</i> , <b>2003</b> , 57, 280-9	4.2	46
209	Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. <i>British Journal of Cancer</i> , <b>1991</b> , 64, 578-82	8.7	46
208	Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e96767	3.7	45
207	Genetic basis and clonal evolution of human prostate cancer. <i>Advances in Cancer Research</i> , <b>1996</b> , 68, 225-55	5.9	45
206	Flow cytometric DNA analysis of 199 histologically favourable or unfavourable non-Hodgkin lymphomas. <i>Journal of Pathology</i> , <b>1989</b> , 157, 27-36	9.4	44
205	Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue. <i>European Urology</i> , <b>2016</b> , 69, 1120-8	10.2	43
204	Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. <i>Cancer Genetics and Cytogenetics</i> , <b>1996</b> , 89, 7-13		43
203	Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization. <i>Cytogenetic and Genome Research</i> , <b>1992</b> , 60, 190-3	1.9	43
202	Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. <i>Leukemia</i> , <b>2018</b> , 32, 1643-1656	10.7	42
201	Extrachromosomal gene amplification in acute myeloid leukemia; characterization by metaphase analysis, comparative genomic hybridization, and semi-quantitative PCR. <i>Genes Chromosomes and Cancer</i> , <b>1993</b> , 8, 185-9	5	42
200	KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine. <i>European Journal of Pharmaceutical Sciences</i> , <b>2017</b> , 98, 30-39	5.1	41
199	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. <i>Leukemia</i> , <b>2017</b> , 31, 301-309	10.7	41
198	Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. <i>Carcinogenesis</i> , <b>2009</b> , 30, 1032-40	4.6	41

197	A novel strategy for microarray quality control using Bayesian networks. <i>Bioinformatics</i> , <b>2003</b> , 19, 2031-8	8.2	41
196	A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. <i>British Journal of Cancer</i> , <b>2001</b> , 84, 1344-7	8.7	41
195	Cigarette smoking alters sympathoadrenal regulation by decreasing the density of beta 2-adrenoceptors. A study of monitored smoking cessation. <i>Journal of Cardiovascular Pharmacology</i> , <b>1991</b> , 17, 923-8	3.1	41
194	High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e39801	3.7	40
193	The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. <i>Genes Chromosomes and Cancer</i> , <b>2011</b> , 50, 499-509	5	39
192	Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. <i>Cancer Research</i> , <b>2010</b> , 70, 7851-61	10.1	39
191	Critical comparison of virtual screening methods against the MUV data set. <i>Journal of Chemical Information and Modeling</i> , <b>2009</b> , 49, 2168-78	6.1	38
190	Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. <i>Neoplasia</i> , <b>2010</b> , 12, 877-88	6.4	37
189	Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. <i>Oncogene</i> , <b>2012</b> , 31, 3597-606	9.2	37
188	Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays. <i>Neoplasia</i> , <b>2003</b> , 5, 397-404	6.4	37
187	Primary undifferentiated small cell carcinoma of the esophagus: clinicopathological and flow cytometric evaluation of eight cases. <i>Journal of Surgical Oncology</i> , <b>1991</b> , 46, 174-7	2.8	37
186	The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R113	8.3	36
185	Interaction with ErbB4 promotes hypoxia-inducible factor-1 signaling. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 9659-9671	5.4	36
184	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , <b>2007</b> , 8, 84	4.5	36
183	BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. <i>European Journal of Human Genetics</i> , <b>2006</b> , 14, 167-72	5.3	36
182	Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. <i>Cancer Causes and Control</i> , <b>2001</b> , 12, 223-30	2.8	36
181	Functional profiling of precursor MicroRNAs identifies MicroRNAs essential for glioma proliferation. <i>PLoS ONE</i> , <b>2013</b> , 8, e60930	3.7	36
180	Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. <i>Leukemia</i> , <b>2017</b> , 31, 1187-1195	10.7	35

179	A functional genetic screen reveals new regulators of $\beta$ -integrin activity. <i>Journal of Cell Science</i> , <b>2012</b> , 125, 649-61	5.3	35
178	Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 2344-50	12.9	35
177	Clinical and functional target validation using tissue and cell microarrays. <i>Current Opinion in Chemical Biology</i> , <b>2002</b> , 6, 97-101	9.7	35
176	Physical mapping of chromosome 17 cosmids by fluorescence in situ hybridization and digital image analysis. <i>Genomics</i> , <b>1994</b> , 20, 125-8	4.3	35
175	Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. <i>Oncogene</i> , <b>2012</b> , 31, 2075-89	9.2	34
174	Analysis of kinase gene expression patterns across 5681 human tissue samples reveals functional genomic taxonomy of the kinome. <i>PLoS ONE</i> , <b>2010</b> , 5, e15068	3.7	32
173	Comparison of Affymetrix data normalization methods using 6,926 experiments across five array generations. <i>BMC Bioinformatics</i> , <b>2009</b> , 10 Suppl 1, S24	3.6	32
172	Analysis and Visualization of Gene Expression Microarray Data in Human Cancer Using Self-Organizing Maps. <i>Machine Learning</i> , <b>2003</b> , 52, 45-66	4	32
171	Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. A fluorescence microscopic and flow cytometric study. <i>Atherosclerosis</i> , <b>1988</b> , 69, 257-68	3.1	32
170	MicroRNA-135b regulates ER $\alpha$ and HIF1AN and affects breast and prostate cancer cell growth. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1287-300	7.9	31
169	BRCA2 mutations in 154 finnish male breast cancer patients. <i>Neoplasia</i> , <b>2004</b> , 6, 541-5	6.4	31
168	Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. <i>Cell Reports</i> , <b>2017</b> , 18, 673-684	10.6	30
167	Individual and stable autoantibody repertoires in healthy individuals. <i>Autoimmunity</i> , <b>2019</b> , 52, 1-11	3	30
166	Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. <i>Molecular Oncology</i> , <b>2018</b> , 12, 1639-1655	7.9	30
165	Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3689-96	5.9	30
164	miR-183 in prostate cancer cells positively regulates synthesis and serum levels of prostate-specific antigen. <i>European Urology</i> , <b>2015</b> , 68, 581-8	10.2	30
163	Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6570-81	12.9	30
162	Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. <i>Molecular Cancer Research</i> , <b>2012</b> , 10, 597-604	6.6	30

161	Fiber-FISH: experiences and a refined protocol. <i>Genetic Analysis, Techniques and Applications</i> , <b>1996</b> , 12, 179-184		30
160	Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells. <i>The Histochemical Journal</i> , <b>1990</b> , 22, 498-506		30
159	The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. <i>BMC Genomics</i> , <b>2017</b> , 18, 629	4.5	29
158	Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. <i>British Journal of Cancer</i> , <b>2001</b> , 84, 116-9	8.7	29
157	Automated peak detection and cell cycle analysis of flow cytometric DNA histograms. <i>Cytometry</i> , <b>1994</b> , 16, 250-5		29
156	Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis. <i>Oncogene</i> , <b>2014</b> , 33, 3538-43	9.3	28
155	Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis. <i>Bioinformatics</i> , <b>2014</b> , 30, i497-504	7.2	28
154	Genome-wide scanning for linkage in Finnish breast cancer families. <i>European Journal of Human Genetics</i> , <b>2004</b> , 12, 98-104	5.3	27
153	Androgen receptor gene alterations in Finnish male breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2003</b> , 77, 167-70	4.4	27
152	A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. <i>Human Genetics</i> , <b>2005</b> , 117, 307-16	6.3	27
151	Interactions between Notch- and hypoxia-induced transcriptomes in embryonic stem cells. <i>Experimental Cell Research</i> , <b>2010</b> , 316, 1610-24	4.2	26
150	Genetic changes in familial prostate cancer by comparative genomic hybridization. <i>Prostate</i> , <b>2001</b> , 46, 233-9	4.2	26
149	ANX7 as a bio-marker in prostate and breast cancer progression. <i>Disease Markers</i> , <b>2001</b> , 17, 115-20	3.2	26
148	Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. <i>Leukemia</i> , <b>2019</b> , 33, 1570-1582	10.7	26
147	T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. <i>Haematologica</i> , <b>2019</b> , 104, 338-346	6.6	26
146	15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. <i>Journal of Pathology</i> , <b>2012</b> , 226, 674-86	9.4	25
145	Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2017</b> , 31, 51-57	10.7	24
144	Mechanically stretched chromosomes as targets for high-resolution FISH mapping. <i>Genome Research</i> , <b>1995</b> , 5, 13-20	9.7	24

143	c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. <i>British Journal of Cancer</i> , <b>1996</b> , 73, 620-3	8.7	24
142	GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets. <i>PLoS ONE</i> , <b>2011</b> , 6, e17259	3.7	24
141	Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005424	7.6	24
140	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. <i>Bioinformatics</i> , <b>2020</b> , 36, 3602-3604	7.2	23
139	Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. <i>Human Genetics</i> , <b>2005</b> , 116, 43-50	6.3	23
138	Molecular cytogenetics of human breast cancer. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , <b>1994</b> , 59, 645-52	3.9	23
137	Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e51470	3.7	23
136	Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. <i>Gynecologic Oncology</i> , <b>2017</b> , 144, 621-630	4.9	22
135	Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. <i>Prostate</i> , <b>2012</b> , 72, 789-802	4.2	21
134	Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. <i>European Journal of Human Genetics</i> , <b>2001</b> , 9, 773-9	5.3	21
133	Serum CA 125 in acute pelvic inflammatory disease. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1989</b> , 96, 574-9	3.7	21
132	Inter-laboratory comparison of DNA flow cytometric results from paraffin-embedded breast carcinomas. <i>Breast Cancer Research and Treatment</i> , <b>1990</b> , 17, 59-61	4.4	21
131	DNA ploidy level and cell cycle distribution in ovarian cancer: relation to histopathological features of the tumor. <i>International Journal of Gynecological Pathology</i> , <b>1988</b> , 7, 1-11	3.2	21
130	Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells. <i>Cell Death and Disease</i> , <b>2014</b> , 5, e1043	9.8	20
129	HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. <i>Oncogene</i> , <b>2012</b> , 31, 1299-310	9.2	20
128	Molecular cytogenetics: diagnosis and prognostic assessment. <i>Current Opinion in Biotechnology</i> , <b>1992</b> , 3, 623-31	11.4	20
127	DNA flow cytometric analysis indicates that many breast cancers detected in the first round of mammographic screening have a low malignant potential. <i>International Journal of Cancer</i> , <b>1988</b> , 42, 697-702	7.5	20
126	Medicine: profile of a tumour. <i>Nature</i> , <b>2004</b> , 428, 379-82	50.4	19

125	From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. <i>Seminars in Cancer Biology</i> , <b>2001</b> , 11, 395-401	12.7	19
124	A strategy for identifying putative causes of gene expression variation in human cancers. <i>Journal of the Franklin Institute</i> , <b>2004</b> , 341, 77-88	4	18
123	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. <i>Blood Advances</i> , <b>2020</b> , 4, 274-286	7.8	18
122	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. <i>Breast Cancer: Targets and Therapy</i> , <b>2017</b> , 9, 185-198	3.9	17
121	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. <i>Blood Advances</i> , <b>2017</b> , 1, 2257-2268	7.8	17
120	The human gene for xanthine dehydrogenase (XDH) is localized on chromosome band 2q22. <i>Cytogenetic and Genome Research</i> , <b>1995</b> , 68, 61-3	1.9	17
119	Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>1996</b> , 56, 57-63	2	17
118	Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 790	9.8	17
117	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 2060-2071	6.1	17
116	Building an international consortium for tracking coronavirus health status. <i>Nature Medicine</i> , <b>2020</b> , 26, 1161-1165	50.5	16
115	Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data. <i>Bioinformatics</i> , <b>2015</b> , 31, 3815-21	7.2	16
114	Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs. <i>BMC Bioinformatics</i> , <b>2012</b> , 13, 112	3.6	16
113	Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. <i>Carcinogenesis</i> , <b>2007</b> , 28, 1040-5	4.6	16
112	BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. <i>Journal of Medical Genetics</i> , <b>2003</b> , 40, e98	5.8	16
111	ITGB1-dependent upregulation of Caveolin-1 switches TGF $\beta$ signalling from tumour-suppressive to oncogenic in prostate cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 2338	4.9	15
110	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1356-1366	7.5	15
109	A novel transcript, VNN1-AB, as a biomarker for colorectal cancer. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 2077-84	7.5	15
108	Morphological spot counting from stacked images for automated analysis of gene copy numbers by fluorescence in situ hybridization. <i>Journal of Biomedical Optics</i> , <b>2002</b> , 7, 109-22	3.5	15



107	Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. <i>Prostate</i> , <b>2019</b> , 79, 1505-1513	4.2	14
106	Plasticity of blood- and lymphatic endothelial cells and marker identification. <i>PLoS ONE</i> , <b>2013</b> , 8, e74293	3.7	14
105	Simulation Toolbox for 3D-FISH Spot-Counting Algorithms. <i>Real Time Imaging</i> , <b>2002</b> , 8, 203-212		14
104	Intrinsic resistance to PIM kinase inhibition in AML through p38-mediated feedback activation of mTOR signaling. <i>Oncotarget</i> , <b>2016</b> , 7, 37407-37419	3.3	14
103	Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 435-443	8.7	14
102	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. <i>Blood Cancer Journal</i> , <b>2015</b> , 5, e309	7	13
101	Flow cytometric analysis of tumour DNA profile related to response to radiotherapy and survival in inoperable lung cancer. <i>Acta Oncologica</i> , <b>1990</b> , 29, 983-8	3.2	13
100	Nuclear DNA content of non-endemic Burkitt's lymphoma. <i>Journal of Clinical Pathology</i> , <b>1987</b> , 40, 1201-5	3.9	13
99	Growth properties and composition of cytoskeletal and cytocontractile proteins in aortic cells isolated and cultured from normal and atherosclerotic rabbits. <i>Atherosclerosis</i> , <b>1984</b> , 52, 13-26	3.1	13
98	Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data. <i>Molecular and Cellular Proteomics</i> , <b>2015</b> , 14, 3274-83	7.6	12
97	Human Protein Atlas charts a diverse terrain. <i>Trends in Biotechnology</i> , <b>2006</b> , 24, 195-7	15.1	12
96	A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. <i>Oncotarget</i> , <b>2016</b> , 7, 28510-22	3.3	12
95	Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer. <i>Personalized Medicine</i> , <b>2019</b> , 16, 51-65	2.2	12
94	Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. <i>Molecular Oncology</i> , <b>2017</b> , 11, 1156-1171	7.9	11
93	Combined epithelial marker analysis of tumour budding in stage II colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , <b>2019</b> , 5, 63-78	5.3	11
92	associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. <i>Journal of Pathology: Clinical Research</i> , <b>2017</b> , 3, 123-138	5.3	10
91	Prognostic value of cells with more than 5c DNA content in node-negative breast cancer as determined by image cytometry from tissue sections. <i>Human Pathology</i> , <b>1993</b> , 24, 1348-53	3.7	10
90	Prognostic assessment in stage I ovarian cancer using a discriminant analysis with clinicopathological and DNA flow cytometric data. <i>Gynecologic and Obstetric Investigation</i> , <b>1989</b> , 27, 213-6	2.5	10

89	Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. <i>Genome Medicine</i> , <b>2011</b> , 3, 63	14.4	9
88	Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screens. <i>Journal of Computer-Aided Molecular Design</i> , <b>2009</b> , 23, 227-39	4.2	9
87	A decade of cancer gene profiling: from molecular portraits to molecular function. <i>Methods in Molecular Biology</i> , <b>2010</b> , 576, 61-87	1.4	9
86	Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17. <i>Cytogenetic and Genome Research</i> , <b>1998</b> , 82, 189-91	1.9	9
85	Low biological aggressiveness of screen-detected lung cancers may indicate over-diagnosis. <i>International Journal of Cancer</i> , <b>1996</b> , 66, 6-10	7.5	9
84	Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. <i>BMC Cancer</i> , <b>2016</b> , 16, 378	4.8	9
83	Anagrelide for Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1676-1687	12.9	9
82	Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. <i>Leukemia</i> , <b>2019</b> , 33, 2548-2553	10.7	8
81	Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours. <i>Journal of Pathology</i> , <b>2018</b> , 245, 101-113	9.4	8
80	Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours. <i>Journal of Cellular and Molecular Medicine</i> , <b>2018</b> , 22, 2220-2230	5.6	8
79	Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia. <i>Leukemia</i> , <b>2017</b> , 31, 1048-1058	10.7	8
78	ARLTS1 and prostate cancer risk--analysis of expression and regulation. <i>PLoS ONE</i> , <b>2013</b> , 8, e72040	3.7	8
77	Correlation between serum tumor marker levels and tumor proliferation in small cell lung cancer. <i>Tumor Biology</i> , <b>1988</b> , 9, 287-92	2.9	8
76	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , <b>2017</b> , 8, 22606-22615	3.3	8
75	Implementing a functional precision medicine tumor board for acute myeloid leukemia. <i>Cancer Discovery</i> , <b>2021</b> ,	24.4	8
74	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , <b>2020</b> , 105, 1527-1538	6.6	8
73	Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 2535-45	7.5	7
72	Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e26595	3.7	7

71	Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. <i>BMC Medical Genomics</i> , <b>2009</b> , 2, 26	3.7	7
70	Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma. <i>PLoS ONE</i> , <b>2012</b> , 7, e50819	3.7	7
69	High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. <i>Journal of Molecular Biochemistry</i> , <b>2016</b> , 5, 12-22	0.2	7
68	Functional genomics and transcriptomics of prostate cancer: promises and limitations. <i>BJU International</i> , <b>2005</b> , 96 Suppl 2, 10-5	5.6	6
67	Primary invasive and in situ vaginal carcinoma. Flow cytometric analysis of DNA aneuploidy and cell proliferation from archival paraffin-embedded tissue. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>1989</b> , 32, 247-51	2.4	6
66	Elevated serum HMFG antigen levels in breast and ovarian cancer patients measured with a sandwich ELISA. <i>International Journal of Cancer</i> , <b>1988</b> , 2, 28-33	7.5	6
65	NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. <i>Analytical Cellular Pathology</i> , <b>2005</b> , 27, 169-73	3.4	6
64	Genetic Instability of Influenza pH1N1 Viruses. <i>Genome Announcements</i> , <b>2014</b> , 2,		5
63	Alignment of gene expression profiles from test samples against a reference database: New method for context-specific interpretation of microarray data. <i>BioData Mining</i> , <b>2011</b> , 4, 5	4.3	5
62	Cancer genomes. <i>Clinical Chemistry</i> , <b>2010</b> , 56, 1660-4	5.5	5
61	Nationwide cancer family ascertainment using Finnish Cancer Registry data on family names and places of birth for 35,761 prostate cancer patients. <i>International Journal of Cancer</i> , <b>2000</b> , 88, 307-12	7.5	5
60	Analysis of DNA synthesis in herpes simplex virus infected cells by dual parameter flow cytometry. <i>Archives of Virology</i> , <b>1989</b> , 107, 215-23	2.6	5
59	Suppression of autologous mixed leukocyte reaction in type 1 diabetes mellitus by in vivo-activated T lymphocytes. <i>Clinical Immunology and Immunopathology</i> , <b>1989</b> , 52, 406-13		5
58	Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation. <i>Carcinogenesis</i> , <b>2013</b> , 34, 2000-9	4.6	4
57	Comparative genomic hybridization gaining in popularity. <i>Trends in Genetics</i> , <b>1996</b> , 12, 237-238	8.5	4
56	Evaluation of camera requirements for comparative genomic hybridization. <i>Cytometry</i> , <b>1996</b> , 25, 394-8		4
55	Genetic Risk Score for Serum 25-Hydroxyvitamin D Concentration Helps to Guide Personalized Vitamin D Supplementation in Healthy Finnish Adults. <i>Journal of Nutrition</i> , <b>2021</b> , 151, 281-292	4.1	4
54	Circulating tumor DNA in early-stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?. <i>EMBO Molecular Medicine</i> , <b>2015</b> , 7, 994-5	12	3

53	Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes. <i>Epigenomics</i> , <b>2010</b> , 2, 683-9	4.4	3
52	KRAS oncogene rearrangements and gene fusions: unexpected rare encounters in late-stage prostate cancers. <i>Cancer Discovery</i> , <b>2011</b> , 1, 12-3	24.4	3
51	Integrated breast cancer genomics. <i>Cancer Cell</i> , <b>2006</b> , 10, 453-4	24.3	3
50	Abstract 3977: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells <b>2011</b> ,		3
49	Multomics and digital monitoring during lifestyle changes reveal independent dimensions of human biology and health. <i>Cell Systems</i> , <b>2021</b> ,	10.6	3
48	Monensin Induced Oxidative Stress Reduces Prostate Cancer Cell Migration and Cancer Stem Cell Population <b>2012</b> ,		2
47	P26. MicroRNA expression profiling and functional screening in bone metastatic breast cancer cells. <i>Cancer Treatment Reviews</i> , <b>2008</b> , 34, 22	14.4	2
46	Abstract 3175: Genomic and transcriptomic data integration in chronic myelomonocytic leukemia reveals a novel fusion gene involving onco-miR-125b-2 <b>2012</b> ,		2
45	Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. <i>Blood</i> , <b>2012</b> , 120, 871-871	2.2	2
44	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. <i>Leukemia</i> , <b>2020</b> , 34, 2780-2784	10.7	2
43	STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells. <i>Translational Oncology</i> , <b>2021</b> , 14, 101027	4.9	2
42	The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 580-588	7.1	2
41	Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference. <i>Breast Cancer Research</i> , <b>2005</b> , 7, 1	8.3	1
40	RESPONSE: Re: Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 153-154	9.7	1
39	Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. <i>Blood</i> , <b>2018</b> , 132, 2763-2763	2.2	1
38	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. <i>Blood</i> , <b>2018</b> , 132, 264-264	2.2	1
37	High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 4641-4641	2.2	1
36	Novel Activating STAT5B Mutations As Drivers Of T-ALL. <i>Blood</i> , <b>2013</b> , 122, 3863-3863	2.2	1

35	Landscape of Mutations in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , <b>2014</b> , 124, 2367-2367	2.2	1
34	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , <b>2017</b> , 130, 854-854	2.2	1
33	Association of tamoxifen resistance and lipid reprogramming in breast cancer		1
32	Molecular Cytogenetics of Solid Tumor Progression <b>1996</b> , 68-78		1
31	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , <b>2012</b> , 120, 288-288	2.2	1
30	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , <b>2021</b> , 15, 2507-2543	7.9	1
29	Predictive Response Biomarkers for BET Inhibitors in AML. <i>Blood</i> , <b>2018</b> , 132, 2749-2749	2.2	0
28	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. <i>Translational Oncology</i> , <b>2021</b> , 15, 101290	4.9	0
27	High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma. <i>Journal of Pathology: Clinical Research</i> , <b>2021</b> , 7, 482-494	5.3	0
26	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 71	9.8	0
25	Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. <i>Cancer Research Communications</i> , <b>2022</b> , 2, 172-181		0
24	Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.. <i>Nature Communications</i> , <b>2022</b> , 13, 1691	17.4	0
23	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. <i>Scientific Reports</i> , <b>2021</b> , 11, 23565	4.9	0
22	Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 3002-3005	1.9	
21	Cancer genome analysis: a landscape seen from many angles. <i>Drug Discovery Today Disease Mechanisms</i> , <b>2007</b> , 4, 269-276		
20	Application of Microarray Technologies for Translational Genomics <b>2005</b> , 361-374		
19	Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients. <i>Blood</i> , <b>2018</b> , 132, 2774-2774 <sup>2</sup>		
18	Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. <i>Blood</i> , <b>2014</b> , 124, 917-917	2.2	

- 17 Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. *Blood*, **2014**, 124, 3505-3505 2.2
- 16 The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. *Blood*, **2014**, 124, 2203-2203 2.2
- 15 Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. *Blood*, **2014**, 124, 2046-2046 2.2
- 14 Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse. *Blood*, **2014**, 124, 1022-1022 2.2
- 13 AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. *Blood*, **2014**, 124, 2163-2163 2.2
- 12 A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. *Blood*, **2014**, 124, 3139-3139 2.2
- 11 BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. *Blood*, **2015**, 126, 2462-2462 2.2
- 10 JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. *Blood*, **2015**, 126, 867-867 2.2
- 9 Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.. *Journal of Clinical Oncology*, **2016**, 34, 604-604 2.2
- 8 Immune Cell Profiling in CML Bone Marrow By Multiplex Immunohistochemistry. *Blood*, **2016**, 128, 1897-1897 2.2
- 7 Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. *Blood*, **2011**, 118, 2487-2487 2.2
- 6 Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. *Blood*, **2011**, 118, 936-936 2.2
- 5 Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. *Blood*, **2012**, 120, 1302-1302 2.2
- 4 Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. *Blood*, **2013**, 122, 1668-1668 2.2
- 3 Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. *Blood*, **2013**, 122, 3828-3828 2.2
- 2 Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. *Blood*, **2013**, 122, 482-482 2.2
- 1 High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. *Blood*, **2013**, 122, 2719-2719 2.2